BR112018070064A2 - composições farmacêuticas estáveis para administração tópica e uso das mesmas - Google Patents

composições farmacêuticas estáveis para administração tópica e uso das mesmas

Info

Publication number
BR112018070064A2
BR112018070064A2 BR112018070064-9A BR112018070064A BR112018070064A2 BR 112018070064 A2 BR112018070064 A2 BR 112018070064A2 BR 112018070064 A BR112018070064 A BR 112018070064A BR 112018070064 A2 BR112018070064 A2 BR 112018070064A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
topical administration
stable pharmaceutical
formula
present
Prior art date
Application number
BR112018070064-9A
Other languages
English (en)
Inventor
Salama Paul
Menahem Becker Oren
Mann Brickman Chaim
Original Assignee
Vidac Pharma Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vidac Pharma Ltd. filed Critical Vidac Pharma Ltd.
Publication of BR112018070064A2 publication Critical patent/BR112018070064A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

a presente invenção se refere a novas composições farmacêuticas para administração tópica de um composto de fórmula i e métodos de tratamento ou prevenção de câncer ou estados pré-cancerígenos ou distúrbios hiperproliferativos benignos, através da administração da composição a um indivíduo em necessidade do mesmo. em particular, a presente invenção fornece uma formulação estável de composto ativo de fórmula i útil para o tratamento de distúrbios, tais como queratose actínica.
BR112018070064-9A 2016-03-28 2017-03-28 composições farmacêuticas estáveis para administração tópica e uso das mesmas BR112018070064A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662313836P 2016-03-28 2016-03-28
US62/313,836 2016-03-28
PCT/IL2017/050381 WO2017168416A1 (en) 2016-03-28 2017-03-28 Stable pharmaceutical compositions for topical administration and uses thereof

Publications (1)

Publication Number Publication Date
BR112018070064A2 true BR112018070064A2 (pt) 2019-02-12

Family

ID=59963752

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018070064-9A BR112018070064A2 (pt) 2016-03-28 2017-03-28 composições farmacêuticas estáveis para administração tópica e uso das mesmas

Country Status (10)

Country Link
US (1) US20200297620A1 (pt)
EP (1) EP3435990B1 (pt)
JP (1) JP2019512536A (pt)
CN (1) CN108778263A (pt)
AU (1) AU2017242155B2 (pt)
BR (1) BR112018070064A2 (pt)
CA (1) CA3017432A1 (pt)
HU (1) HUE054241T2 (pt)
IL (1) IL261929B (pt)
WO (1) WO2017168416A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018083705A1 (en) 2016-11-07 2018-05-11 Vidac Pharma Ltd. Use of hexokinase 2/mitochondria-detaching compounds for treating hexokinase-2 (hk2)-expressing cancers
US10682346B2 (en) 2016-11-07 2020-06-16 Vidac Pharma Ltd. Use of hexokinase 2/mitochondria-detaching compounds for activating immune responses

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6469061B1 (en) 2001-04-04 2002-10-22 Ramot University Authority For Applied Research And Industrial Development Limited Jasmonate pharmaceutical composition for treatment of cancer
GB2391471B (en) * 2002-08-02 2005-05-04 Satishchandra Punambhai Patel Pharmaceutical compositions
US7425651B2 (en) 2003-12-02 2008-09-16 Ramot At Tel-Aviv University Ltd. Jasmonate derivative compounds, pharmaceuticals compounds and methods of use thereof
AU2006322845A1 (en) 2005-12-07 2007-06-14 Sepal Pharma Ltd. Jasmonate derivatives, pharmaceutical compositions and methods of use thereof
US20090291904A1 (en) 2005-12-07 2009-11-26 Yoel Kashman Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof
CN101326172A (zh) * 2005-12-07 2008-12-17 思珀药品有限公司 茉莉酮酸酯衍生物、药物组合物及它们的使用方法
MX2008015266A (es) * 2006-06-01 2009-02-10 Nobera Pharma Sl Uso del alopurinol para el tratamiento de la eritrodisestesia palmo-plantar.
BRPI0714046A2 (pt) * 2006-07-10 2013-04-24 Univ Ramot mÉtodos de combinaÇço para tratar cÂncer
US9284252B2 (en) * 2009-06-09 2016-03-15 Sepal Pharma Ltd. Use of jasmonate ester derivatives for treating benign hyperproliferative skin disorders
WO2010143180A1 (en) 2009-06-09 2010-12-16 Sepal Pharma Ltd. Use of jasmonate ester derivatives for treating benign hyperproliferative skin disorders
JP5840604B2 (ja) * 2009-06-11 2016-01-06 フォトキュア エイエスエイ 半固体組成物および医薬品
JP2014526519A (ja) * 2011-09-16 2014-10-06 ナノケア テクノロジーズ，インコーポレイティド ジャスモネート化合物の組成物および使用方法
CN104159594A (zh) * 2011-10-13 2014-11-19 托马斯·盖德克 用于皮肤病治疗的凯莫瑞c15肽的局部制剂
CA2863658C (en) * 2012-02-03 2023-03-14 Emory University Immunostimulatory compositions, particles, and uses related thereto
CN103908440B (zh) * 2013-01-09 2016-12-28 正大天晴药业集团股份有限公司 一种多烯磷脂酰胆碱胶囊及其制备方法

Also Published As

Publication number Publication date
JP2019512536A (ja) 2019-05-16
IL261929B (en) 2021-01-31
CA3017432A1 (en) 2017-10-05
WO2017168416A1 (en) 2017-10-05
AU2017242155A1 (en) 2018-10-11
EP3435990A1 (en) 2019-02-06
EP3435990B1 (en) 2021-01-27
US20200297620A1 (en) 2020-09-24
CN108778263A (zh) 2018-11-09
AU2017242155B2 (en) 2021-03-25
HUE054241T2 (hu) 2021-08-30
IL261929A (en) 2018-10-31
EP3435990A4 (en) 2019-11-27

Similar Documents

Publication Publication Date Title
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
CL2019002255A1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas.
BR112017022604A2 (pt) composto, composição farmacêutica, uso de um composto e de uma combinação, e, combinação
BR112019009529A2 (pt) novos derivados de quinolina
BR112019008458A2 (pt) 1,2,4-triazolonas 2,4,5-trisubstituídas.
BR112017023764A2 (pt) derivados de ciclohexano substituído por amido
BR112018015273A2 (pt) derivados de benzimidazol como moduladores de ror-gama
BR112017012327A8 (pt) benzamidas substituídas por 1,3-tiazol-2-il.
EA201892734A1 (ru) ПРОИЗВОДНЫЕ АЗАБЕНЗИМИДАЗОЛА В КАЧЕСТВЕ ИНГИБИТОРОВ pI3K BETA
BR112016018604A2 (pt) Benzimidazol-2-aminas como inibidores de midh1
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
BR112018071408A2 (pt) “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
EA201690102A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
BR112015023948A2 (pt) composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
MX2013003635A (es) Compuestos de n-heteroarilo.
BR112015026238A8 (pt) composto dihidropirazino-pirazina, composição farmacêutica que o compreende, uso do composto, métodos para inibir ou medir a fosforilação e para inibir a atividade da proteína quinase, bem como kit
BR112017026287A2 (pt) composições de hidroxipropil beta-ciclodextrina e métodos
BR112016007329A2 (pt) composto, composição farmacêutica, e, método para tratamente de uma condição ou doença mediada por hsf1
DOP2015000005A (es) Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
BR112018007068A2 (pt) derivados de quinoxalina e piridopirazina como inibidores de pi3kbeta
BR112019018615A2 (pt) compostos antimicrobianos, composições e usos dos mesmos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements